Avience Biomedicals IPO GMP Today: Is This SME IPO Worth Watching?

The SME IPO market continues to attract investor attention, and Avience Biomedicals IPO is one of the latest public issues generating significant buzz. With a strong presence in the biotechnology and diagnostics sector, the company has gained interest not only for its business fundamentals but also for its rising Grey Market Premium (GMP).

As of June 20, 2026, **Avience Biomedicals IPO GMP** stands at ₹85, indicating strong demand in the unofficial market and an estimated listing gain of around 40.87% over the upper price band.

About Avience Biomedicals

Avience Biomedicals Limited operates in the biotechnology, genomics, and in-vitro diagnostics (IVD) segments. The company manufactures and distributes a wide range of healthcare products, including molecular diagnostic kits, rapid test kits, hematology analyzers, biochemistry analyzers, reagents, and medical equipment.

Its products are used by hospitals, pathology laboratories, diagnostic centers, research institutes, and healthcare organizations across India and international markets.

Why Investors Are Tracking This IPO

The healthcare and diagnostics industry has witnessed rapid growth over the last few years. Increasing healthcare awareness, rising diagnostic testing demand, and technological advancements have created long-term opportunities for companies operating in this sector.

Avience Biomedicals plans to use the IPO proceeds to establish a new manufacturing facility, strengthen working capital, and support future expansion initiatives. These growth plans have contributed to positive investor sentiment.

Avience Biomedicals IPO GMP Trend

The grey market premium has shown a consistent upward trend:

• June 15, 2026: ₹40
• June 16, 2026: ₹70
• June 17, 2026: ₹75
• June 18, 2026: ₹75
• June 19, 2026: ₹85
• June 20, 2026: ₹85

The steady increase in GMP reflects growing market confidence ahead of the company’s listing.

Key Strengths

• Diversified portfolio of diagnostic and healthcare products.
• Strong industry experience and management expertise.
• Expanding distribution network across domestic and international markets.
• Focus on affordable and cost-effective healthcare solutions.
• Growing demand for diagnostic testing and healthcare infrastructure.

Risks to Consider

Like every IPO, Avience Biomedicals also carries certain risks:

• High dependence on regulatory approvals and compliance.
• Intense competition within the diagnostics and medical devices industry.
• Dependence on key suppliers for critical raw materials.
• Continued investment requirements in research and development.

Final Thoughts

Avience Biomedicals IPO has emerged as a closely watched SME issue due to its healthcare-focused business model, expansion plans, and strong grey market performance. While the GMP indicates positive listing expectations, investors should remember that GMP is only an unofficial indicator and should not be the sole factor behind investment decisions.

A thorough evaluation of the company’s financial performance, business fundamentals, industry outlook, and valuation remains essential before applying for the IPO. For investors seeking exposure to India’s growing healthcare and diagnostics sector, Avience Biomedicals IPO may be worth monitoring closely.